The four-drug guidelines for heart failure with reduced ejection fraction are well established to cut hospitalizations and a new economic analysis in JAMA suggests that the hospital cost-savings more than cover the cost of the drugs themselves.
- Quadruple GDMT for HFrEF (combining ARNIs, beta-blockers, MRAs, and SGLT2is) has strong data backing its ability to reduce hospitalizations.
- However, the combined financial impact of implementing the full regimen after a hospitalization hasn’t been quantified until now.
To model the cost offset of applying GDMT, researchers analyzed Medicare-linked cost data across 50.5k hospitalized HFrEF patients aged 65+ with one year of post-discharge follow-up.
- On average, the one-year total healthcare costs were $41,802 per patient, with $25,172 of that due to all-cause hospitalizations.
Researchers then projected the financial impact of fewer hospitalizations from GDMT.
- Quadruple GDMT was associated with an 87% relative reduction in HF hospitalizations and a 61% reduction in all-cause hospitalizations.
- That translated to $9,780 in lower hospitalization-associated expenditures per patient annually (a 23.4% relative cost reduction).
More specifically, the net cost decrease depended almost entirely on drug pricing, which is where things get more complicated
- Annual drug costs ranged widely (from $1,223 to $16,136) depending on the pricing source and specific agents used within each class.
- The resulting net annual figure ranged from $8,556 in savings to $6,347 in added net cost, with most four-drug combos leading to net savings.
That means the drug selection determines the economics.
- When clinicians can access lower-cost agents within each drug class (particularly generics) quadruple therapy becomes cost-saving.
The Takeaway
Quadruple GDMT doesn’t just lead to better HFrEF outcomes, it leads to lower financial burden on hospitals, and ultimately the healthcare system. That’s a win for everyone from the payor to the patient, meaning there’s probably no reason to not follow these guidelines.
